Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Oct 17, 2024 6:33am
365 Views
Post# 36269423

Is the end of trial near…..

Is the end of trial near…..Arch manangement announced on X yesterday that it will be presenting at 2 conferences starting Oct 23 in San Diego California and in November in Stockholm Sweden.

Now one thing we know is Arch CEO is extremely frugal with his operating budget and the company does not have a history of presenting at these type of target rich events.

As we delve a little deeper we know Arch has raised almost $1M new capital in the past 3 months and they have been dosing at 5 sites in Turkey for 8 months. I believe this money was raised to get Arch across tge finish line!

Arch management has provided zero updates on the progress of dosing in Turkey with ultimate goal of 240 patients.

Now one cannot imagine that Arch would attend these two premiere conferences  that will have a target rich audience with many of the top industry analysts, Institutional Investors and Big Pharma Executives attending if they did not have compelling data to present. This my friends is the TSN turning point. We currently have zero Institutional Investors and no analydts after RJ analalyst left the firm, this will be changing very soon. 

In my humble opinion I believe this is a huge turning point for Arch and this clearly signals that the phase 2 trial in Turkey is close to wrapping up after 8 months of dosing with zero adverse reactions.

Good luck to all the longs,  2025 is going to reward those who stuck it out!!!

https://x.com/archbiopartners/status/1846613349775106184
<< Previous
Bullboard Posts
Next >>